Gilead Sciences, Inc. (GILD)

NMS – Real Time Price. Currency in USD

136.50

+0.73 (0.54%)

Market open: Aug 12, 2026, 10:21 AM EDT

135.07

-0.70 (-0.51%)

Previous after-hours: Aug 11, 2026, 7:51 PM EDT

10.08.2026

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

Gilead's R&D pipeline gained momentum in the first half of 2026, adding several potential growth drivers. Sales of Biktarvy, the flagship of Gilead's HIV franchise, rose 6.9% year-over-year and 12.2% QoQ to ~$3.77 billion in the second quarter. On the other hand, Livdelzi, a PPARδ agonist, generated $167 million in revenue for Gilead, up 114.1% YoY.

07.08.2026

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.

06.08.2026

Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings

Gilead Sciences is upgraded to a cautious 'Buy' after Q2/26, supported by robust revenue growth and raised guidance. GILD's HIV portfolio, especially Biktarvy and Descovy, continues to drive sales, but revenue concentration poses mid-2030s patent cliff risk. Recent acquisitions inflated Q2 operating losses, yet free cash flow surged to $3.4B, and debt remains manageable relative to cash generation.

05.08.2026

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.

05.08.2026

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). The updated release reads: GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Yea.

05.08.2026

Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript

05.08.2026

Gilead Sciences Q2 Earnings Call Highlights

Gilead Sciences NASDAQ: GILD reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology and Livdelzi in liver disease. The company raised its full-year base business sales outlook and increased its expected HIV growth rate, while reporting a quarterly non-GAAP loss driven by acquisition-related research and development charges.

Videos

No Data

There is no data to display

Press releases

05.08.2026

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

04.08.2026

AHF Crowns Gilead Corporate Welfare King

LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF Crowns Gilead Corporate Welfare King.

04.08.2026

Gilead Sciences Announces Second Quarter 2026 Financial Results

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026. “Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026,” said Dan.

Gilead Sciences, Inc. (GILD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Gilead Sciences, Inc. (GILD)

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript

Gilead Sciences Q2 Earnings Call Highlights

Videos

No Data

Press releases

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

AHF Crowns Gilead Corporate Welfare King

Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript

Gilead Sciences Q2 Earnings Call Highlights

Videos

No Data

Press releases

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

AHF Crowns Gilead Corporate Welfare King

Gilead Sciences Announces Second Quarter 2026 Financial Results

Search stocks

Gilead Sciences, Inc. (GILD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Gilead Sciences, Inc. (GILD)

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript

Gilead Sciences Q2 Earnings Call Highlights

Videos

No Data

Press releases

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

AHF Crowns Gilead Corporate Welfare King

Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings

GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript

Gilead Sciences Q2 Earnings Call Highlights

Videos

No Data

Press releases

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

AHF Crowns Gilead Corporate Welfare King

Gilead Sciences Announces Second Quarter 2026 Financial Results